Fig. 5
From: Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer
Cys528 mutation of CRM1 abolished the ability of S109 to inhibit proliferation. a Whole cell lysates were extracted from the cells stable expressing wild type or C528S mutant CRM1. Western blot analyses the expression level of CRM1 in both SKOV-3 cells. b Wild type and C528S mutant SKOV-3 cells were treated with S109 at the indicated concentrations for 24 h. Nuclear proteins was extracted and subjected to immunoblot analysis. c Wild type and C528S mutant SKOV-3 cells treated with indicated doses of S109 for 12 h. The whole cell lysates were analyzed by immunoblotting. d Growth inhibition assay in wild type and C528S mutant cells. Cells were seeded in 96-well plates and incubated with S109 at indiated concentrations for 72 h. Growth inhibition was analyzed by the CCK-8 assay. All the data are presented as mean ± SEM in three repeats (*P < 0.05)